DanCann Pharma A/S sigter mod at accelerere forretnings- og indtægtsvækst: Omfattende strategiopdatering følger i oktober

DanCann Pharma er i øjeblikket i gang med at udarbejde en ny strategisk retning med henblik på at føre selskabet mod succes. Denne strategiske genovervejelse understreger Selskabets engagement i at imødekomme de skiftende behov hos dets kunder og interessenter.

Selskabet har sat sig som mål at opnå en omsætning på cirka 7 millioner danske kroner inden for det nuværende regnskabsår, med planer om udvidelse i det efterfølgende år som følge af introduktionen af nye produkter, der i øjeblikket er under udvikling.

I øjeblikket arbejder DanCann Pharma på at udarbejde sin første ansøgning i overensstemmelse med den seneste aftale indgået med MYCB1.
Selskabet er aktivt involveret i forberedelsen af de første to ansøgninger til det nye produktformat, der fokuserer på orale dråber (olier).

Derudover har DanCann Pharma indledt flere dialoger om fremtiden for Biotech Pharm1 med interesserede parter. Både joint ventures og fuldstændige overtagelser drøftes i disse samtaler.

DanCann Pharma vil give en omfattende opdatering om sin nye strategi og vækstplaner i oktober.
Denne kommende meddelelse forventes at give indblik i Selskabets vision for fremtiden og dets ambitioner om at levere værdi til sine patienter, kunder og investorer.

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm and side listed on OTCQB Venture Market in USA (OTCQB: DCPXF). For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO

Phone: +45 2963 6920

E-mail: jkr@dancann.com

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.